LAS VEGAS, June 2, 2020
LAS VEGAS, June 2, 2020 /PRNewswire/ -- Diabetic Peripheral Neuropathy Market will increase because of the rising global burden of diabetes that is driving prevalence of diabetic neuropathy, advancement in early diagnosis as well as launch of the promising therapies which will positively impact DPN market.
DelveInsight added a new report titled "Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.
Key Highlights from Diabetic Peripheral Neuropathy Market report are:
Diabetic Peripheral Neuropathy is a painful condition that is caused by nerve damage from diabetes. It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes.
There is a huge patient population pool affected by the disease; the Diabetic Peripheral Neuropathy market report covers the disease epidemiology that is segmented into Total Diagnosed Prevalent Cases of DPN, Total Prevalent Cases of Painful DPN and Gender-specific Prevalent cases of DPN in the 7MM from 2017 to 2030.
The total Painful Diabetic Peripheral Neuropathy Prevalent Cases were 3,857,945 in the United States in 2020. Also, females are more affected by the disease as compared to males for Diabetic Peripheral Neuropathy Prevalent in the US in 2020.
Among the 7MM, the US accounts for 58% of the overall market size of DPN. Among the EU-5 countries, Germany accounts for the highest market size for DPN. Diabetic Peripheral Neuropathy market has a diverse pipeline with several promising therapies. Also, Gene therapy has been developed for DPN pain management. Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grünenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies. The potential launch of these emerging drugs will aid in overall market growth. There are a couple of market drivers which will be driving the market. One such factor will be an early diagnosis of the DPN because of the advancements happening in the DPN diagnostic approaches. As the patient pool for diabetic peripheral neuropathy is quite large, and there is no treatment for reversal of disease, this indication withholds a plethora of opportunities for drug development companies. No doubt that the clinical pipeline contains a large number of drugs; however, previously multiple clinical trial failures gave a setback and limited the research and development in the DPN domain. So far it has been clear that path traversed is not easy in DPN research as the long-term clinical trials and low success rate in meeting the clinical endpoints may become threats for the investors to fund further.
There are many key players robustly involved in developing potential drugs and they are a ray of hope for DPN patients such as:
5. ISC 17536
8. GRC 17356
And many others
The key players involved in Diabetic Peripheral Neuropathy market are:
3. WinSanTor, Inc
4. Regenacy Pharmacuticals
5. Ichnos Science
7. Grünenthal GmbH
8. Glenmark Pharmaceuticals
And many others
The reasons for buying Diabetic Peripheral Neuropathy market report:
Table of contents
1. Key Insights
2. Executive summary
3. Diabetic Peripheral Neuropathy Market Overview at a Glance
4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology
5. Diabetic Peripheral Neuropathy Disease Background and Overview
6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population
6.1. Key Findings
6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy in 7MM
6.3. United States
6.9. United Kingdom
7. Diabetic Peripheral Neuropathy Treatment and Management
8. Diabetic Peripheral Neuropathy Unmet need
9. Diabetic Peripheral Neuropathy Marketed Drugs
9.1. Key cross competition
9.2. Qutenza: Grünenthal
9.3. Tarlige: Daiichi Sankyo
10. Diabetic Peripheral Neuropathy Emerging drugs
10.1. Key cross competition
10.2. VM202: Helixmith
10.3. NYX-2925: Aptinyx
10.4. WST-057: WinSanTor
10.5. Ricolinostat: Regenacy Pharmaceuticals
10.6. Cebranopadol: Grünenthal
10.7. ISC 17536: Ichnos Science
10.8. NRD135S.E1: Novaremed
10.9. MEDI7352: AstraZeneca
10.10. Trazodone/Gabapentin: Angelini
11. Diabetic Peripheral Neuropathy Market Size
11.1. Key Findings
11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM
11.3. Diabetic Peripheral Neuropathy Market Outlook: 7 MM
11.4. United States
11.10. United Kingdom
12. Diabetic Peripheral Neuropathy Reimbursement policies
13. Market Drivers
14. Market Barriers
15. SWOT Analysis
16. KOL Views
17. Diabetic Peripheral Neuropathy Case Report
18. A Case Report of Diabetic Peripheral Neuropathy
21. Diabetic Peripheral Neuropathy Report Methodology
22. DelveInsight Capabilities
24. About DelveInsight
Request a WebEx Demo to get a walk-through of the Diabetic Peripheral Neuropathy Market Report: https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market
Diabetic Peripheral Neuropathy Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in the 7 MM.
Diabetic Peripheral Neuropathy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market.
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.